title: Effect of extended olanzapine administration on POMC and neuropeptide Y mRNA levels in the male rat amygdala and hippocampus.
abstract: BACKGROUND
  Neuropeptides play an important role in various neural pathways, being able to control a wide spectrum of physiological responses. Neuropeptide Y (NPY) and proopiomelanocortin (POMC) functions are quite well studied, however little is known about their action at the level of limbic structures. The present work was focused on the expression of the aforementioned peptides in this brain structure of rats treated with olanzapine, a second generation neuroleptic drug. The detailed purpose of this experiment was the evaluation of potential relationships between chronic olanzapine administration and NPY and POMC mRNA expression in the amygdala and hippocampal formation.
  
  
  METHODS
  The studies were carried out on adult, male Sprague-Dawley rats that were divided into 2 groups: control and experimental animals treated with olanzapine (28 day-long intraperitoneal injection). All individuals were sacrificed under anaesthesia, then the amygdaloid complexes and hippocampi were excised. Total mRNA was isolated from homogenized samples of both structures and the RT-PCR method was used for estimation of NPY and POMC gene relative expression.
  
  
  RESULTS
  Prolonged olanzapine administration is reflected in qualitatively different changes in expression of NPY and POMC mRNA in the rat amygdala and hippocampus. Interestingly enough, olanzapine did not affect NPY expression, but significantly increased the POMC level in both examined regions.
  
  
  CONCLUSIONS
  Olanzapine can affect amygdalar and hippocampal neuronal populations by the modulation of neuropeptide activity. Importantly, it may suggest the existence of an alternative mode of its action. Undoubtedly this hypothetic regulatory mechanism requires further pharmacological and neurostructural study.
authors.affiliation: Department of Histology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland. Electronic address: apalasz@sum.edu.pl.
authors.forename: Artur
authors.initials: A
authors.lastname: Pałasz
authors.affiliation: Department of Biochemistry, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Warszawa, Poland.
authors.forename: Magdalena
authors.initials: M
authors.lastname: Bandyszewska
authors.affiliation: Department of Histology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.
authors.forename: Ewa
authors.initials: E
authors.lastname: Rojczyk
authors.affiliation: Department of Histology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.
authors.forename: Ryszard
authors.initials: R
authors.lastname: Wiaderkiewicz
mesh_terms: D000679:Amygdala / Q000187:drug effects*; D000818:Animals; D001569:Benzodiazepines / Q000008:administration & dosage*; D015870:Gene Expression / Q000187:drug effects; D006624:Hippocampus / Q000187:drug effects*; D008297:Male; D009478:Neuropeptide Y / Q000235:genetics*; D000077152:Olanzapine; D011333:Pro-Opiomelanocortin / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D009478:Neuropeptide Y; D012333:RNA, Messenger; D001569:Benzodiazepines; D011333:Pro-Opiomelanocortin; D000077152:Olanzapine
keywords: Amygdala; Hippocampus; NPY; Olanzapine; POMC